Tirzepatide has emerged as a groundbreaking treatment for terzipetide supplier type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its supply have become key topics for patients and healthcare practitioners. While tirzepatide has been approved by regulatory agencies, its expensive nature presents a signif